RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,247,064.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total value of $163,277.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Trading Down 2.7 %

Shares of NASDAQ RXST traded down $1.42 during midday trading on Monday, reaching $51.56. The company had a trading volume of 328,151 shares, compared to its average volume of 484,877. The business’s 50-day simple moving average is $50.98 and its 200 day simple moving average is $53.95. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54. The stock has a market cap of $1.91 billion, a P/E ratio of -41.21 and a beta of 1.22.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same quarter last year, the business earned ($0.40) earnings per share. The firm’s revenue was up 67.6% on a year-over-year basis. Analysts predict that RxSight, Inc. will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On RxSight

A number of institutional investors and hedge funds have recently made changes to their positions in RXST. Amalgamated Bank boosted its holdings in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after buying an additional 207 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in RxSight by 3.2% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after purchasing an additional 242 shares during the last quarter. RiverPark Advisors LLC raised its position in RxSight by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after purchasing an additional 297 shares during the last quarter. CWM LLC raised its position in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the last quarter. Finally, Arizona State Retirement System raised its position in RxSight by 5.0% in the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock valued at $467,000 after purchasing an additional 373 shares during the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RXST has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Oppenheimer decreased their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. BTIG Research boosted their price objective on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Finally, Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.